JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (7): 53-57.doi: 10.6040/j.issn.1671-7554.0.2014.841

Previous Articles     Next Articles

Clinical efficacy of BSD2000 deep hyperthermia combined with chemotherapy of TP regimen for advanced ovarian cancer

CUI Yong1, ZHANG Rongxiang2, WANG Fuli3, WANG Guoying4, FENG Jianlin5, ZHANG Haixia1   

  1. 1. Department of Oncology, Shouguang People's Hospital, Shouguang 262700, Shandong, China;
    2. Department of Out-Patient, Shouguang People's Hospital, Shouguang 262700, Shandong, China;
    3. Department of Oncology, Zibo Central Hospital, Zibo 255000, Shandong, China;
    4. Department of Internal Medicine, Affiliated Hospital of Weifang Medical University, Weifang 261000, Shandong, China;
    5. Department of Radiology, Shouguang People's Hospital, Shouguang 262700, Shandong, China
  • Received:2014-11-16 Revised:2015-03-02 Published:2015-07-10

PDF (PC)

242

Abstract: Objective To observe the clinical efficacy of BSD2000 deep hyperthermia combined with chemotherapy of docetaxel plus cisplatin (TP) regimen in the treatment of advanced ovarian cancer. Methods A total of 39 patients with advanced ovarian cancer were randomly divided into two groups: treatment group (n=20) receiving BSD2000 deep hyperthermia plus chemotherapy of TP regimen, and control group (n=19) undergoing chemotherapy of TP regimen. Results For the treatment and control group, the objective response rate (RR) was 90.0% vs 62.2%, RR of ascites was 55.0% vs 21.1%, quality of life score was 70.0% vs 31.6%, with statistically significant differences between the two groups (all P<0.05). The one-year and two-year survival rates for the treatment and control group were 77.8% vs 66.7% and 55.5% vs 44.4%, with no statistical difference (both P>0.05). Conclusion BSD2000 deephyperthermia combined with chemotherapy of TP regimen can significantly improve objective response rate and quality of life for patients with advanced ovarian cancer, and toxicity can be well tolerated.

Key words: Hyperthermia, Ovarian cancer, Docetaxel, Cisplatin, Drug therapy

CLC Number: 

  • R737.31
[1] Burger RA, Brady MF, Bookman MA, et al. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a gynecologic oncology group study[J]. J Clin Oncol, 2014, 32(12):1210-1217.
[2] Suidan RS, St Clair CM, Lee SJ, et al. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer[J]. Gynecol Oncol, 2014, 134(3):468-472.
[3] Toffart AC, Moro-Sibilot D, Couraud S, et al. Evaluation of RECIST in chemotherapy-treated lung cancer: the pharmacogenoscan study[J]. BMC Cancer, 2014, 14(1):989.
[4] Müller V, Fuxius S, Steffens CC, et al. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study[J]. Oncol Res Treat, 2014, 37(12):748-755.
[5] Kautio AL, Haanp M, Kautiainen H, et al. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy[J]. Anticancer Res, 2011, 31(10):3493-3496.
[6] Teefey P, Bou Zgheib N, Apte SM, et al. Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers[J]. Am J Obstet Gynecol, 2013, 208(6):501-507.
[7] Muenyi CS, Trivedi AP, Helm CW, et al. Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells[J]. Toxicol Sci, 2014, 139(1):74-82.
[8] 杨孟祥, 赵军, 王彦文. BSD2000深部热疗联合PT方案化疗在非小细胞肺癌中的应用[J]. 中国肺癌杂志, 2010, 13(2):132-135. YANG Mengxiang, ZHAO Jun, WANG Yanwen. BSD2000 deep hyperthermia combined with chemotherapy of PT regimen in patients with non-small cell lung cancer[J]. Chinese Journal of Lung Cancer, 2010, 13(2):132-135.
[9] Yan SY, Chen MM, Fan JG, et al. Therapeutic mechanism of treating SMMC-7721 liver cancer cells with magnetic fluid hyperthermia using Fe2O3 nanoparticles[J]. Braz J Med Biol Res, 2014, 47(11):947-959.
[10] Wessalowski R, Schneider DT, Mils O, et al. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours:an open-label, non-randomised, single-institution, phase 2 study[J]. Lancet Oncol, 2013, 14(9):843-852.
[11] Bruggmoser G, Bauchowitz S, Canters R, et al. Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia:quality management in regional deep hyperthermia[J]. Strahlenther Onkol, 2012, 188(Suppl 2):198-211.
[12] Bruggmoser G, Bauchowitz S, Canters R, et al. Quality assurance for clinical studies in regional deep hyperthermia[J]. Strahlenther Onkol, 2011, 187(10):605-610.
[13] 张力, 李毅学, 张立广, 等. 热疗诱导人肝癌细胞HepG2的凋亡[J]. 中国老年学杂志, 2013, 33(6):1342-1344.
[14] 李灿宇, 张自森, 薛长年, 等. 热灌注顺铂治疗晚期卵巢癌恶性腹腔积液的临床疗效[J]. 中国老年学杂志, 2012, 32(17):3656-3658.
[15] 赵军, 王宝中, 盛延兴, 等. 放化疗结合相控阵聚焦热疗治疗直肠癌术后局部区域复发的临床观察[J]. 中华肿瘤防治杂志, 2009, 16(21):1691-1693. ZHAO Jun, WANG Baozhong, SHENG Yanxing, et al. Curative effect of radiotherapy and chemotherapy combined with focus phased array thermotherapy for rectal cancer with recurrence after resection[J]. Chinese Journal of Cancer Prevention and Treatment, 2009, 16(21):1691-1693.
[1] SUO Dongyang, SHEN Fei, GUO Hao, LIU Lichang, YANG Huimin, YANG Xiangdong. Expression and mechanism of Tim-3 in animal model of drug-induced acute kidney injury [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 1-6.
[2] DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30.
[3] ZHAO Ming, NIU Jie, LI Fangqin, WANG Aihong, PANG Qiuxia, CHEN Meini, ZHOU Lizhen, ZHAO Jumei. Effects of salinomycin combined with cisplatin on the proliferation and apoptosis of human gastric cancer cell line MKN-45 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 31-35.
[4] LU Heng, LIU Yanguo, LI Shuguang, CHEN Xiaokang, TIAN Qi, YI Cuihua, WANG Xiuwen. Regulation of epithelial ovarian carcinoma SKOV-3 cell migration by YKL-40 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 33-38.
[5] ZHAO Lu, JIAO Jun, ZHANG Teng, JIAO Xinlin, CUI Baoxia. Expression of LXRα in ovarian carcinoma and effects of T0901317 on SKOV3 cell line [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 49-53.
[6] XIAO Junchao, JIANG Wen, NAN Hui, WANG Peirong. A recombinant adenovirus fiber knob protein sensitizes ovarian cancer cells to cetuximab therapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(5): 1-5.
[7] ZHAO Yunxia, SONG Jing, ZHANG Cancan, LIN Xueyan, WEI Wei, TIAN Yongjie. CXXC4 promotes sensitivity to chemotherapy drugs in epithelial ovarian cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 24-29.
[8] XU Zhihong, WU Xiaohua, YAO Tiezhu, WANG Xiaoxiang, DUAN Xiaoyang, SHI Jian. Relationship between mir-99a expression and prognosis of epithelial ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 77-80.
[9] YANG Lu, LIU Yanguo, LI Jisheng, WANG Xiuwen. Effect of bufalin on chemosensitivity to cisplatin in non-small cell lung cancer and the underlying mechanisms [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(3): 6-11.
[10] CHEN Jing, LI Chunyan, ZHAO Miaoqing, CUI Jingjing, ZHANG Na, FU Yibing. Expression of EZH2 protein and its role in ovarian epithelial tumor [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 65-70.
[11] WANG Hui. Clinical observation of triple therapy of moxifloxacin and esomeprazole magnesium for Helicobacter Pylori [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(8): 52-56.
[12] ZHANG Min, WANG Xuefeng. Killing effect of apoptotic-tumor-cell-loaded dendritic cells on laryngeal carcinoma cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(7): 32-36.
[13] QIU Huihui1， YE Liping1， WEN Youfeng2， LI Dan1， SONG Jia1. Effects of IL-6 on the expressions of bcl-2，cyclinD1 and VEGF in ovarian cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 17-21.
[14] LI Yan, WEI Wei, LV Shuqing, TIAN Yongjie. Effects of PARP-1 on angiogenesis of ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 97-101.
[15] ZHANG Miaoci, LI Ping, HA Minwin. Clinical observation of recombinant human endostatin combined with gemcitabine in the treatment of platinum-resistant recurrent ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 55-59.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd